This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Click here for VYNDAQEL®▼ (tafamidis) Prescribing Information.
The development of the consensus meeting report was organised and funded by Pfizer. It was reviewed by Pfizer for compliance
and accuracy purposes only.
Background: ATTR-CM is a rare, progressive heart condition often underdiagnosed and misdiagnosed due to its non-specific symptoms and systemic barriers in the healthcare system1,2.
Objectives: Provide a roadmap to help guide cardiology and primary care teams in diagnosing, managing and referring ATTR-CM patients. Clarify accountability, applicable guidelines, and referral criteria to ensure timely and accurate diagnosis and optimal outcomes.
Methods: Between May and August 2025, committee members came together to produce a document containing actionable solutions to address the underlying issues in the diagnosis and treatment of ATTR-CM.
Outcomes: The roadmap identifies key challenges and provides recommendations to improve detection and treatment of patients with ATTR-CM.
Committee vision statement: Improved identification and earlier treatment of patients with ATTR-CM by 2028.
The consensus meeting report was co-authored by: Prof Marianna Fontana, Prof Lisa Anderson, Dr Sotiris Antoniou, Dr William Moody, Dr Chris Arden, Rebecca Hyland, Bal Bains, Vincent Graham Nesan Nicholas, Prof Gerald Carr-White, Dr Carol Whelan, Sheela Upadhyaya, Eric Low and Kaity Mcafferty.
The development of this consensus meeting report was organised and funded by Pfizer. This report is intended to be viewed online and is not for printing.
A consensus meeting report detailing the outputs and recommendations from an expert committee to improve diagnosis and referral for ATTR-CM patients in the UK, following a consensus-building workshop. Pfizer reviewed the document for accuracy and compliance purposes only, with outputs reflecting the consensus reached in the meeting and content developed by independent advisory firms who facilitated the workshop.
Click here for VYNDAQEL®▼ (tafamidis) Prescribing Information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2026 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-13971. December 2025